Abstract
Aim: To investigate the impact of moderate-intensity exercise and pre-exercise blood glucose concentrations (BG) on the demand of orally administered carbohydrates (CHO) to maintain euglycemia (> 70 - 180 mg/dL) during endurance exercise sessions performed over 5 consecutive days on either a regular (100%) or reduced dose (75%) of insulin degludec (IDeg) in people with type 1 diabetes (T1D). Methods: Nine participants with T1D (four women, mean age 32.1 ± 9.0 years, BMI 25.5 ± 3.9 kg/m2, glycated hemoglobin 55 ± 7 mmol/mol [7.2 ± 0.6%]) on IDeg were randomized to cycle for 55 minutes at moderate intensity (63 ± 7% VO2max) for 5 consecutive days on either 100% or 75% of their regular IDeg dose. The exercise accumulating effect was analysed via one-way-ANOVA for repeated measures (day x administered CHO). The influence of pre-exercise BG was analysed by one-way ANOVA or Kruskal-Wallis stratified for BG quartiles and Spearman correlation. The effect of IDeg dose (100% vs. 75%) on given CHO was calculated via Wilcoxon or student's t-test (p<0.05). Results: No exercise accumulating effect was found (p>0.05) but CHO intake was significantly related to pre-exercise BG (r=-0.45; p<0.0001). Conclusion: Pre-exercise BG had a significant influence on the demand of orally administered CHO to maintain euglycemia during exercise over 5 consecutive days. Disclosure M.L. Eckstein: Research Support; Self; Novo Nordisk A/S. O. Moser: Research Support; Self; Abbott, Dexcom, Inc., Novo Nordisk A/S. A. Mueller: None. P. Birnbaumer: None. F. Aberer: None. G. Koehler: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S, Sanofi-Aventis Deutschland GmbH. C. Sourij: None. H. Kojzar: None. P.N. Pferschy: None. P. Dietz: None. R.M. Bracken: None. P. Hofmann: None. H. Sourij: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis. Funding Novo Nordisk Pharma GmbH
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
